Advocacy intelligence hub — real-time data for patient organizations
Jules Bordet Institute
PRG Science & Technology Co., Ltd. — PHASE2
in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Zokinvy
Sentynl Therapeutics, Inc.
Zokinvy
(LONAFARNIB)Orphan drugSentynl Therapeutics, Inc.
Farnesyltransferase Inhibitor [EPC]
12.1 Mechanism of Action Lonafarnib inhibits farnesyltransferase to prevent farnesylation and subsequent accumulation of progerin and progerin-like pr...
Nicolas LEVY, MD, M. D
Assistance Publique des Hopitaux de Marseille
📍 ENCINITAS, CA
William A Gahl, M.D.
National Human Genome Research Institute (NHGRI)
📍 Bethesda, Maryland
Min Young Kim, MD, PhD
CHA University
Bulmaro Cisneros
Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV)
Marlon De Ita
National Polytechnical Institute
Ian García-Aguirre
National Polytechnical Institute